BRAF and melanoma: Similar to acquired resistance seen with other targeted therapies, including EGFR mutant lung cancers and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutant melanomas, there are case reports demonstrating acquired resistance to crizotinib (Katayama et al., 2011).